{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:35:42Z","timestamp":1783722942257,"version":"3.55.0"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CB21\/13\/00091"],"award-info":[{"award-number":["CB21\/13\/00091"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2026,4]]},"abstract":"Abstract<\/jats:title>\n \n Objective<\/jats:title>\n \n To evaluate the effectiveness and tolerability of dolutegravir\/lamivudine (\n DTG<\/jats:styled-content>\n \/\n 3TC<\/jats:styled-content>\n ) at 96\u2009weeks in virologically suppressed persons with\n HIV<\/jats:styled-content>\n , both overall and across subgroups, within\n CoRIS<\/jats:styled-content>\n , a large multicenter cohort in Spain, in 2018\u20132023\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n We included treatment\u2010experienced adults with\n HIV<\/jats:styled-content>\n who were virologically suppressed (viral load <50 copies\/\n mL<\/jats:styled-content>\n ) when switching to\n DTG<\/jats:styled-content>\n \/\n 3TC<\/jats:styled-content>\n . We calculated the proportion maintaining viral suppression (\n VS<\/jats:styled-content>\n ), change in\n CD4<\/jats:styled-content>\n cell counts, virological failure (\n VF<\/jats:styled-content>\n ; two consecutive viral load (\n VL)<\/jats:styled-content>\n \u226550 copies\/\n mL<\/jats:styled-content>\n or one \u22651000 copies\/\n mL<\/jats:styled-content>\n ), and discontinuations due to adverse events (\n AEs<\/jats:styled-content>\n ) up to 96\u2009weeks post\u2010switch. Outcomes were stratified by sex, age, region of origin, antiretroviral regimen at switch, and previous\n VF<\/jats:styled-content>\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 2058 participants (22.5% women), 95.9% maintained\n VS<\/jats:styled-content>\n , 2.2% experienced\n VF<\/jats:styled-content>\n , and 2.2% discontinued due to\n AEs<\/jats:styled-content>\n . In multivariable analysis, no significant differences in\n VS<\/jats:styled-content>\n ,\n VF<\/jats:styled-content>\n or\n CD4<\/jats:styled-content>\n change were observed across most subgroups. Participants aged \u226550\u2009years were more likely to maintain\n VS<\/jats:styled-content>\n , had lower\n VF<\/jats:styled-content>\n risk, and a smaller\n CD4<\/jats:styled-content>\n increase compared with <50\u2009years. Prior\n VF<\/jats:styled-content>\n was associated with lower likelihood of maintaining\n VS<\/jats:styled-content>\n and higher\n VF<\/jats:styled-content>\n risk. Switching from\n 2NRTIs<\/jats:styled-content>\n \u2009+\u2009\n PI<\/jats:styled-content>\n or\n 2NRTIs<\/jats:styled-content>\n \u2009+\u2009\n INSTI<\/jats:styled-content>\n increased risk of\n VF<\/jats:styled-content>\n compared with\n NRTIs<\/jats:styled-content>\n +\n NNRTI<\/jats:styled-content>\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n DTG<\/jats:styled-content>\n \/\n 3TC<\/jats:styled-content>\n showed high effectiveness and tolerability at 96\u2009weeks, with consistent outcomes across most subgroups. Previous\n VF<\/jats:styled-content>\n reduced the likelihood of sustained\n VS<\/jats:styled-content>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/hiv.70183","type":"journal-article","created":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T01:04:07Z","timestamp":1767229447000},"page":"546-559","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness and tolerability of dolutegravir\/lamivudine in virologically suppressed people with\n HIV<\/scp>\n at 96\u2009weeks in a multicentre cohort"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7016-716X","authenticated-orcid":false,"given":"In\u00e9s","family":"Su\u00e1rez\u2010Garc\u00eda","sequence":"first","affiliation":[{"name":"Infectious Diseases Group, Department of Internal Medicine Infanta Sof\u00eda University Hospital, Infanta Sofia University Hospital and Henares University Hospital Foundation for Biomedical Research and Innovation (FIIB HUIS HHEN) Madrid Spain"},{"name":"Department of Medicine, Faculty of Medicine, Health and Sports Universidad Europea de Madrid Madrid Spain"},{"name":"CIBERINFEC Carlos III Health Institute Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Alejos","sequence":"additional","affiliation":[{"name":"Independent Researcher Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Moreno","sequence":"additional","affiliation":[{"name":"CIBERINFEC Carlos III Health Institute Madrid Spain"},{"name":"National Centre for Epidemiology Carlos III Health Institute Madrid Spain"},{"name":"Programa de Doctorado en Ciencias Biom\u00e9dicas y Salud P\u00fablica, IMIENS Universidad Nacional de Educaci\u00f3n a Distancia (UNED) Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"de Miguel","sequence":"additional","affiliation":[{"name":"CIBERINFEC Carlos III Health Institute Madrid Spain"},{"name":"HIV Unit, Department of Internal Medicine II Hospital Universitario La Paz\u2010Carlos III Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4374-6940","authenticated-orcid":false,"given":"Teresa","family":"Ald\u00e1miz\u2010Echevarr\u00eda","sequence":"additional","affiliation":[{"name":"CIBERINFEC Carlos III Health Institute Madrid Spain"},{"name":"Department of Clinical Microbiology and Infectious Diseases Gregorio Mara\u00f1\u00f3n General University Hospital Madrid Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM) Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2512-6107","authenticated-orcid":false,"given":"Lucio Jes\u00fas","family":"Garc\u00eda\u2010Fraile","sequence":"additional","affiliation":[{"name":"CIBERINFEC Carlos III Health Institute Madrid Spain"},{"name":"Department of Internal Medicine Hospital Universitario de La\u2009Princesa Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Tasias Pitarch","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit Hospital Universitario y Polit\u00e9cnico La Fe Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desir\u00e9e","family":"P\u00e9rez Martinez","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Hospital Universitario San Agust\u00edn Avil\u00e9s Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Antela","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit Hospital Cl\u00ednico Universitario Santiago de Compostela Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2843-1094","authenticated-orcid":false,"given":"Santiago","family":"Moreno","sequence":"additional","affiliation":[{"name":"CIBERINFEC Carlos III Health Institute Madrid Spain"},{"name":"Department of Infectious Diseases. Hospital Universitario Ram\u00f3n y Cajal Alcal\u00e1 University, IRYCIS Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7485-2252","authenticated-orcid":false,"given":"Inma","family":"Jarr\u00edn","sequence":"additional","affiliation":[{"name":"CIBERINFEC Carlos III Health Institute Madrid Spain"},{"name":"National Centre for Epidemiology Carlos III Health Institute Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"CoRIS cohort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"European AIDS Clinical Society.EACS Guidelines. Version 12.12024."},{"key":"e_1_2_11_3_1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Department of Health and Human Sciences.Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV.2024."},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1243"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac130"},{"key":"e_1_2_11_6_1","unstructured":"diGiambenedettoS WalmsleyS GrinsztejnB et al.Real\u2010world Experience With the 2\u2010Drug Regimen Dolutegravir and Lamivudine in Women With HIV: A Systematic Literature Review. HIV Drug Therapy Glasgow Conference November 20252022. Glasgow UK."},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1293.2000.00019.x"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003478"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2011.06.002"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac036"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/v15020322"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002787"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/25787489.2023.2239564"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab429"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13643"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13500"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-024-00604-9"},{"key":"e_1_2_11_18_1","unstructured":"LetangE.Systematic Literature Review of Real\u2010world Experience With the 2\u2010Drug Regimen Dolutegravir + Lamivudine (DTG + 3TC) in People With HIV\u20101 (PWH) Aged \u226550\u2009Years (eP.A.048). 19th EACS Conference; 2023; Warsaw Poland. 18\u201321 October 2023."},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-013-0107-7"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002266"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2022.11.010"},{"issue":"4","key":"e_1_2_11_22_1","first-page":"410","article-title":"Single tablet regimen with abacavir\/lamivudine\/dolutegravir compared with two\u2010drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study","volume":"27","author":"Baldin G","year":"2019","journal-title":"Infez Med"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad189"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2019.04.009"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae475"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2012.0005"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofu079"},{"key":"e_1_2_11_28_1","unstructured":"Sistema de informaci\u00f3n sobre nuevos diagn\u00f3sticos de VIH.Registro nacional de casos de SIDA. Vigilancia epidemiol\u00f3gica del VIH y SIDA en Espa\u00f1a 2022. Actualizaci\u00f3n 30 de junio de 2023.2022."}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70183","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.70183","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T05:09:55Z","timestamp":1775452195000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.70183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/hiv.70183"],"URL":"https:\/\/doi.org\/10.1111\/hiv.70183","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"assertion":[{"value":"2025-08-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}